Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 16 Feb 2023
Abbott has previously opposed legislation to test strips, but noted an 89% increase in fentanyl deaths in Texas over the past year.
Read Full NewsuniQure navigates FDA's unexpected shift on AMT-130, aiming for accelerated approval for Huntington's disease despite recent regulatory challenges.
Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Christina Briscoe, MD. [LISTEN TIME: 24 minutes]
Over the first 3 months of treatment, over 60% of patients with migraine treated with galcanezumab attained at least a 50% reduction in monthly migraine or headache days.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 28, 2025.
Cheung explores the effect of sparsentan on urinary biomarkers in treatment-naive patients with IgA nephropathy.
ACR Convergence 2025 Recap: Late-Breaking Trials to Know
Tezepelumab Drastically Reduces OCS Use for Asthma in Open-Label Trial
1.
Experts suggest Michelangelo depicted breast cancer in the Sistine Chapel fresco
2.
MCh in Surgical Oncology: Admission, Medical School, Fees, Qualifications Information
3.
Adding Targeted Agent to Perioperative Therapy for RCC May Improve Disease Control
4.
Which women need more than mammograms for breast cancer screening?
5.
Pulled Myeloma Drug Improves Survival in Trial
1.
IL1R2 Inhibition: A New Strategy to Boost Cancer Immunity
2.
Innovative Strategies in Prostate Cancer Management: From Surveillance to Systemic Therapies
3.
The latest research on Thyroid Cancer: Symptoms, Diagnosis, and Treatment Options
4.
Toripalimab + Nab-Paclitaxel in PD-L1+ TNBC: Phase 3 TORCHLIGHT Trial Results
5.
Essential Oncology Updates: Diagnosis, Treatment Advances, Tools & Education Resources
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part I
2.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part IV
3.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia
4.
A New Era in Managing Cancer-Associated Thrombosis
5.
"Lorlatinib Upfront": A Niche but Powerful Option For ALK+ NSCLC
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge